GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

ECC5004

Company
Eccogene
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for ECC5004 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07775404

    A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 351 participants Est. completion 2028-04-20 49 sites
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT05654831

    FTIH of ECC5004 in Healthy and Diabetic Participants

    Not yet reported Eccogene 69 participants Est. completion 2023-11-01 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06268145

    ECC5004 RBA FE Study in Healthy Participants

    Not yet reported Eccogene 14 participants Est. completion 2024-03-29 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06293742

    ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants

    Not yet reported Eccogene 48 participants Est. completion 2024-04-15 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06555822

    A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy Participants

    Not yet reported AstraZeneca 31 participants Est. completion 2025-03-06 1 site
    Other conditions: Healthy Participants
    View official trial listing →
  • Completed NCT NCT06742762

    A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004

    Not yet reported AstraZeneca 16 participants Est. completion 2025-04-20 3 sites
    Other conditions: Renal Impairment
    View official trial listing →
  • Completed NCT NCT06813781

    Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004

    Not yet reported AstraZeneca 33 participants Est. completion 2025-10-02 5 sites
    Other conditions: Hepatic Impairment
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.